Patent ID: 9173960
Filing Date: 2015-11-03
Classification: A61K,A61P,C07K,C12N,Y10S

Abstract:
1. A method of treating a disease mediated by a canonical Wnt signaling pathway comprising the step of administering to a subject in need thereof an effective amount of a composition comprising a low density lipoprotein-related protein 6(LRP6) construct, wherein said construct comprises (a) first and second LRP6 single chain Fv molecules (scFvs) or fragments thereof that bind to LRP6; and (b) a human serum albumin; wherein the first and second scFv molecules or fragments thereof are linked to the N- and C-termini of the human serum albumin, wherein the LRP6 construct inhibits a canonical Wnt signal transduction pathway, and wherein the the LRP6 construct displays no significant potentiation of a Wnt signal in the presence of an LRP6 binding protein, and wherein the disease is a cancer.